Efficacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high-grade cancer of the ovary or peritoneum

Pedro T. Ramirez, Kathleen M. Schmeler, Michael R. Milam, Brian Slomovitz, Judith A. Smith, John J. Kavanagh, Michael Deavers, Charles Levenback, Robert L. Coleman, David M. Gershenson

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Objective: To evaluate the efficacy and safety of letrozole in patients with recurrent platinum- and taxane-resistant estrogen receptor-positive (ER+) high-grade cancer of the ovary or peritoneum. Methods: A single-institution, phase II study was performed in women with recurrent ER+ epithelial carcinoma of the ovary or peritoneum. All patients had measurable disease. Letrozole was administered at a dose of 2.5 mg orally once daily until disease progression or toxicity occurred. Results: Thirty-three patients were enrolled. The median age was 63 years (range, 38 to 83 years). Twenty-three patients (74%) had received three or more prior chemotherapy regimens. The 31 patients evaluable for response received a total of 81 cycles (4 weeks/cycle) of therapy (range, 1 to 14 cycles/patient). The median treatment duration was 8 weeks (range, 4 to 52 weeks). None of the patients had a complete response (CR), 1 (3%) had a partial response (PR), and 7 (23%) had stable disease (SD). The median duration of clinical benefit (SD and PR) was 9 weeks (range, 7 to 46 weeks). The median follow-up for all patients was 25 weeks. All patients were evaluable for toxicity. The most common adverse effects were fatigue (36%) and diaphoresis (21%). No grade 3 or 4 toxicities were reported, and no patients discontinued treatment owing to adverse effects. Eighteen patients (58%) went on to receive additional therapy with other agents. Conclusion: In patients with ER-positive, platinum- and taxane-resistant high-grade ovarian and primary peritoneal cancer treated with letrozole, 26% derived a clinical benefit (SD and PR).

Original languageEnglish (US)
Pages (from-to)56-59
Number of pages4
JournalGynecologic Oncology
Volume110
Issue number1
DOIs
StatePublished - Jul 2008
Externally publishedYes

Fingerprint

letrozole
Peritoneum
Platinum
Ovarian Neoplasms
Therapeutics
taxane

Keywords

  • Letrozole
  • Resistant ovarian and peritoneal cancer

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Efficacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high-grade cancer of the ovary or peritoneum. / Ramirez, Pedro T.; Schmeler, Kathleen M.; Milam, Michael R.; Slomovitz, Brian; Smith, Judith A.; Kavanagh, John J.; Deavers, Michael; Levenback, Charles; Coleman, Robert L.; Gershenson, David M.

In: Gynecologic Oncology, Vol. 110, No. 1, 07.2008, p. 56-59.

Research output: Contribution to journalArticle

Ramirez, PT, Schmeler, KM, Milam, MR, Slomovitz, B, Smith, JA, Kavanagh, JJ, Deavers, M, Levenback, C, Coleman, RL & Gershenson, DM 2008, 'Efficacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high-grade cancer of the ovary or peritoneum', Gynecologic Oncology, vol. 110, no. 1, pp. 56-59. https://doi.org/10.1016/j.ygyno.2008.03.014
Ramirez, Pedro T. ; Schmeler, Kathleen M. ; Milam, Michael R. ; Slomovitz, Brian ; Smith, Judith A. ; Kavanagh, John J. ; Deavers, Michael ; Levenback, Charles ; Coleman, Robert L. ; Gershenson, David M. / Efficacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high-grade cancer of the ovary or peritoneum. In: Gynecologic Oncology. 2008 ; Vol. 110, No. 1. pp. 56-59.
@article{c2820fee077b4b5495d491bb61d9a342,
title = "Efficacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high-grade cancer of the ovary or peritoneum",
abstract = "Objective: To evaluate the efficacy and safety of letrozole in patients with recurrent platinum- and taxane-resistant estrogen receptor-positive (ER+) high-grade cancer of the ovary or peritoneum. Methods: A single-institution, phase II study was performed in women with recurrent ER+ epithelial carcinoma of the ovary or peritoneum. All patients had measurable disease. Letrozole was administered at a dose of 2.5 mg orally once daily until disease progression or toxicity occurred. Results: Thirty-three patients were enrolled. The median age was 63 years (range, 38 to 83 years). Twenty-three patients (74{\%}) had received three or more prior chemotherapy regimens. The 31 patients evaluable for response received a total of 81 cycles (4 weeks/cycle) of therapy (range, 1 to 14 cycles/patient). The median treatment duration was 8 weeks (range, 4 to 52 weeks). None of the patients had a complete response (CR), 1 (3{\%}) had a partial response (PR), and 7 (23{\%}) had stable disease (SD). The median duration of clinical benefit (SD and PR) was 9 weeks (range, 7 to 46 weeks). The median follow-up for all patients was 25 weeks. All patients were evaluable for toxicity. The most common adverse effects were fatigue (36{\%}) and diaphoresis (21{\%}). No grade 3 or 4 toxicities were reported, and no patients discontinued treatment owing to adverse effects. Eighteen patients (58{\%}) went on to receive additional therapy with other agents. Conclusion: In patients with ER-positive, platinum- and taxane-resistant high-grade ovarian and primary peritoneal cancer treated with letrozole, 26{\%} derived a clinical benefit (SD and PR).",
keywords = "Letrozole, Resistant ovarian and peritoneal cancer",
author = "Ramirez, {Pedro T.} and Schmeler, {Kathleen M.} and Milam, {Michael R.} and Brian Slomovitz and Smith, {Judith A.} and Kavanagh, {John J.} and Michael Deavers and Charles Levenback and Coleman, {Robert L.} and Gershenson, {David M.}",
year = "2008",
month = "7",
doi = "10.1016/j.ygyno.2008.03.014",
language = "English (US)",
volume = "110",
pages = "56--59",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Efficacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high-grade cancer of the ovary or peritoneum

AU - Ramirez, Pedro T.

AU - Schmeler, Kathleen M.

AU - Milam, Michael R.

AU - Slomovitz, Brian

AU - Smith, Judith A.

AU - Kavanagh, John J.

AU - Deavers, Michael

AU - Levenback, Charles

AU - Coleman, Robert L.

AU - Gershenson, David M.

PY - 2008/7

Y1 - 2008/7

N2 - Objective: To evaluate the efficacy and safety of letrozole in patients with recurrent platinum- and taxane-resistant estrogen receptor-positive (ER+) high-grade cancer of the ovary or peritoneum. Methods: A single-institution, phase II study was performed in women with recurrent ER+ epithelial carcinoma of the ovary or peritoneum. All patients had measurable disease. Letrozole was administered at a dose of 2.5 mg orally once daily until disease progression or toxicity occurred. Results: Thirty-three patients were enrolled. The median age was 63 years (range, 38 to 83 years). Twenty-three patients (74%) had received three or more prior chemotherapy regimens. The 31 patients evaluable for response received a total of 81 cycles (4 weeks/cycle) of therapy (range, 1 to 14 cycles/patient). The median treatment duration was 8 weeks (range, 4 to 52 weeks). None of the patients had a complete response (CR), 1 (3%) had a partial response (PR), and 7 (23%) had stable disease (SD). The median duration of clinical benefit (SD and PR) was 9 weeks (range, 7 to 46 weeks). The median follow-up for all patients was 25 weeks. All patients were evaluable for toxicity. The most common adverse effects were fatigue (36%) and diaphoresis (21%). No grade 3 or 4 toxicities were reported, and no patients discontinued treatment owing to adverse effects. Eighteen patients (58%) went on to receive additional therapy with other agents. Conclusion: In patients with ER-positive, platinum- and taxane-resistant high-grade ovarian and primary peritoneal cancer treated with letrozole, 26% derived a clinical benefit (SD and PR).

AB - Objective: To evaluate the efficacy and safety of letrozole in patients with recurrent platinum- and taxane-resistant estrogen receptor-positive (ER+) high-grade cancer of the ovary or peritoneum. Methods: A single-institution, phase II study was performed in women with recurrent ER+ epithelial carcinoma of the ovary or peritoneum. All patients had measurable disease. Letrozole was administered at a dose of 2.5 mg orally once daily until disease progression or toxicity occurred. Results: Thirty-three patients were enrolled. The median age was 63 years (range, 38 to 83 years). Twenty-three patients (74%) had received three or more prior chemotherapy regimens. The 31 patients evaluable for response received a total of 81 cycles (4 weeks/cycle) of therapy (range, 1 to 14 cycles/patient). The median treatment duration was 8 weeks (range, 4 to 52 weeks). None of the patients had a complete response (CR), 1 (3%) had a partial response (PR), and 7 (23%) had stable disease (SD). The median duration of clinical benefit (SD and PR) was 9 weeks (range, 7 to 46 weeks). The median follow-up for all patients was 25 weeks. All patients were evaluable for toxicity. The most common adverse effects were fatigue (36%) and diaphoresis (21%). No grade 3 or 4 toxicities were reported, and no patients discontinued treatment owing to adverse effects. Eighteen patients (58%) went on to receive additional therapy with other agents. Conclusion: In patients with ER-positive, platinum- and taxane-resistant high-grade ovarian and primary peritoneal cancer treated with letrozole, 26% derived a clinical benefit (SD and PR).

KW - Letrozole

KW - Resistant ovarian and peritoneal cancer

UR - http://www.scopus.com/inward/record.url?scp=45549096026&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45549096026&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2008.03.014

DO - 10.1016/j.ygyno.2008.03.014

M3 - Article

C2 - 18457865

AN - SCOPUS:45549096026

VL - 110

SP - 56

EP - 59

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -